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Introduction
Cardiovascular diseases remain the main cause of 
morbidity and mortality all over the world. As a result of 
significant developments in the field of prevention and 
improvement of treatment outcomes we are observing 
a steady decrease in mortality due to coronary artery 
disease (CAD) [1]. Largely we owe it to evidence-based 
medicine. Results of large, randomized clinical studies 
constitute the rationale for using drugs with proven 
efficacy that reduce the occurrence of hard end points, 
especially mortality. In Europe 20% of deaths are at-
tributed to CAD [2]. According to recent studies, relative 
incidence of ST-segment elevation myocardial infarction 
(STEMI) is decreasing, while that of non-ST-segment 
elevation myocardial infarction increases (NSTEMI) [3, 
4]. Arterial hypertension remains the most important 
risk factor for cardiovascular diseases, including CAD, 
that leads to numerous premature deaths. Prevalence 
of arterial hypertension is steadily rising – according to 
the results of NATPOL 2011 study it increased from 30% 
to 32% in a Polish population. At this rate, by 2035 this 
number will have increased by half [5]. It is also a well-
known fact that poor control of arterial hypertension cor-
relates with cardiovascular risk in a linear fashion. CAD 
and arterial hypertension are the main etiological factors 
involved in development of heart failure, which affects 
1-2% of adult population. In Poland, the number of pa-
tients living with heart failure is estimated at 800 000 and 
the number is growing. The main cause of increase in 
the frequency of occurrence of heart failure include age-
ing of the population and consequences of increasingly 
more effective treatment of acute conditions, e.g. acute 
coronary syndromes. Patients survive, but suffer from 
late complications, such as heart failure. The number 
of patients suffering from heart failure with preserved 
ejection fraction steadily increases, ranging from 22% to 
73% [6], which is accompanied by a decreasing trend 
for heart failure with reduced ejection fraction. Accord-
ing to the results of Heart Failure Pilot Survey registry, 
which included 6108 patients (1159 from Poland), 
Polish patients are more frequently hospitalized due 
to acute heart failure, develop heart failure at younger 
age and are more severely ill, presenting with higher 
New York Heart Association (NYHA) class on hospital 
admission [7]. The cornerstone of treatment for CAD, 
arterial hypertension and heart failure are b-blockers, 
and among them a non-selective b and a1 receptor an-
tagonist – carvedilol – plays an important role. Clinical 
potential and mechanism of action of carvedilol has 
been thoroughly discussed in our previous publication 
from 2003 [8]. However, due to the appearance of nu-
merous new studies grounding the leading role of carve-
dilol among other b-blockers, we decided to prepare 
another article that would summarize and systematize 
current knowledge and highlight indications for the use 
of carvedilol in patients with cardiovascular disease. 
Pharmacological profile and 
mechanism of action of carvedilol
Carvedilol is a lipophilic chemical compound, it 
does not dissolve in water, it is found as two optic 
enantiomers due to the presence of an asymmetric 
carbon in the molecule and the drug is a mixture of 
those two enantiomers (Figure 1). Carvedilol is rapidly 
absorbed after oral administration and reaches peak 
serum concentration after 1-2 hours. Its half-life amounts 
to 7-10 hours. It binds to serum proteins, especially 
albumin, is metabolized by cytochrome P450 in the 
liver to be excreted with bile. Carvedilol is a non-selec-
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Figure 1. Chemical structure of carvedilol with marked structural 
elements responsible for specific actions of the compound. 
Source: Choroby Serca i Naczyń 2008, tom 5, nr 3, 150
Figure 2. Pleiotropic effects of carvedilol
tive b receptor antagonist, with the greatest affinity to 
b1 receptors, followed by a1 and b2. Inhibition of cardiac 
b receptors results in reduced contractility, heart rate, 
minute output, atrioventricular conduction and ectopic 
activity, while blocking of a1 receptor is responsible 
for vasodilative properties of the drug. The pleiotropic 
properties of carvedilol comprising particularly favor-
able pharmacological profile of the drug have been 
broadly discussed in the recent years (Figure 2) [9]. 
The antioxidative effect of carvedilol associated with the 
carbazole part of the compound has been documented 
most extensively (Figure 1) [10, 11]. Patients who re-
ceived carvedilol during the acute phase of myocardial 
infarction (MI) were characterized by greater superoxide 
dismutase activity, while among patients with a history 
of myocardial infarction carvedilol was associated with 
significantly greater reduction of oxidized LDL com-
pared after 12 months of therapy to atenolol [12]. The 
antioxidative effect of carvedilol was also confirmed in 
patients with stable CAD; three months of treatment 
resulted in an increase in the activity of superoxide dis-
mutase, glutathione peroxidase and catalase – enzymes 
responsible for protection against free radicals and oxi-
dation reactions [13]. The effect of carvedilol on plaque 
stabilization postulated by Wu et al. is also attributed to 
its antioxidative properties, leading to reduced activity 
of metalloproteinases responsible for plaque instability 
[14]. Anti-inflammatory effect is another important ac-
tion of carvedilol. In a group of 52 patients with heart 
failure and impaired left ventricular function (EF<40%) 
treatment with carvedilol was associated with reduction 
of C-reactive protein concentration among patients 
with elevated blood levels of this marker compared to 
metoprolol [15]. Similar observations were made in 
another study that randomized 74 patients with heart 
failure and impaired left ventricular function (EF<40%) 
into receiving carvedilol vs. placebo [16]. After 4 months 
of treatment authors demonstrated significant reduction 
in interleukin 6 (IL-6) and tumor necrosis factor a (TNF- 
a) concentrations among patients receiving carvedilol. 
Clinical application of carvedilol among patients 
with coronary artery disease
Acute coronary syndromes are of clinical presenta-
tions of CAD. According to the 2017 guidelines of the 
European Society of Cardiology (ESC) on management 
of STEMI, oral treatment with b-blockers is indicated in 
patients with heart failure and/or reduced ejection frac-
tion (≤40%). Routine use of these drugs should also be 
considered in all patients after STEMI, who do not have 
contraindications to such a treatment (Table 1) [17]. 
On the other hand, 2015 ESC guidelines on the man-
agement of non-ST-segment elevation acute coronary 
syndromes indicate early initiation of b-blocker therapy 
in all patients with symptoms of angina and without 
contraindications to such a treatment (Table 1) [18].
The CAPRICORN trial was the pivotal study that 
established the position of carvedilol in the treatment 
of patients after MI [19]. This multicenter, randomized, 
placebo-controlled study included 1959 patients after 
MI and reduced left ventricular ejection fraction ≤40% 
(LVEF). Patients were randomly assigned either to 
carvedilol at an initial dose 2x6.25 mg, which was subse-
quently titrated to 2x25mg, or placebo. Primary endpoint 
comprised of all-cause mortality or hospitalization due 
to cardiovascular causes. There were no differences 
with regard to the frequency of primary endpoint oc-
currence, although there was a significant reduction in 
all-cause mortality in the group treated with carvedilol 
compared to placebo (116 [12%] vs. 151 [15%]; hazard 
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ratio [HR] 0.77; 95% confidence interval [CI] 0.60-
0.98; p=0.03) reduction of cardiovascular mortality 
(104 [11%] vs. 139 [14%]; HR 0.75; 95% CI 0.58-0.96; 
p=0.024) and MI (34 [3%] vs. 57 [6%]; HR 0.59; 95% 
CI 0.39-0.90; p=0.014). 
One of the first studies assessing long-term effects 
of b-blocker therapy in patients after MI treated with 
coronary angioplasty was an analysis that included 
2442 patients [20]. Participants were divided into two 
groups – 1661 received a b antagonist and 781 patients 
did not. After 6 months of follow-up, the researchers 
noted lower mortality (2.2% vs. 6.6%; P<0.0001; odds 
ratio [OR] 0.43; 95% CI 0.26-0.73; P=0.0016) as well as 
reduced frequency of cardiovascular events (defined as 
death, recurrent MI or ischemia requiring revasculariza-
tion) (14% vs. 17%; P=0.036) in the group treated with 
a b-blocker compared to patients who did not receive 
such a treatment. The greatest benefit of b-blocker 
treatment was observed in patients with reduced left 
ventricular ejection fraction and multivessel CAD. 
Routine use of b-blockers in combination with 
angiotensin converting enzyme inhibitors (ACEI) or an-
giotensin II receptor blockers (ARB) in all patients after 
STEMI is a class IIa recommendation (Table 1) [17]. 
Konishi et al. conducted a study on 251 patients with MI 
treated with ACEI or ARB. Patients were divided into two 
groups: receiving b-blockers (171 patients, 91 received 
carvedilol and 80 received bisoprolol) vs. not receiving 
b-blockers (80 patients) [21]. After 12 months of fol-
low-up, the authors observed a reduction in all-cause 
mortality in a group of patients receiving the b receptor 
antagonist compared to the control group (7 [4.1%] 
vs. 11 [13.8%]; P=0.006) as well as a reduction in seri-
ous cardiovascular incidents (MI, stroke, hospitalization 
due to cardiovascular causes) (27 [15.8] vs. 29 [36.3]; 
P<0.0001). There were no significant differences be-
tween groups on carvedilol vs. bisoprolol with regard to 
all-cause mortality. However, reduction in the incidence 
of acute heart failure requiring hospitalization was noted 
in the carvedilol group compared to the bisoprolol group 
{6 [6%] vs. 13 [16.3%]; P=0.04). 
Benefits of b-blocker therapy was confirmed in 
a multicenter registry consisting of 20 344 patients, of 
whom 8 510 patients with STEMI treated with primary 
coronary angioplasty were selected [22]. Among all re-
cruited subjects, 6873 were treated with a b-blocker and 
1637 did not receive such a treatment. After a median 
follow-up of 367 days all-cause mortality was significant-
ly lower in the group of patients receiving b-blockers 
compared to patients not treated with b-blockers 
(146 [2.1%] vs. 59 [3.6%]; P<0.001). In a subgroup 
analysis, the benefits of b-blockers were also demon-
strated in low-risk patients, including those with left 
ventricular ejection fraction >40% or single-vessel CAD.
Results of another meta-analysis consisting of 
40 873 patients from 10 observational studies also cor-
Table 1. Place of b-blockers in the European Society of Cardiology guidelines
Recommendation Class Level
Stable coronary artery disease
First-line treatment is indicated with ß-blockers and/or calcium channel blockers to control heart rate and symptoms. I A
Acute coronary syndromes without persistent ST-segment elevation
Early initiation of beta-blocker treatment is recommended in patients with ongoing ischaemic symptoms and 
without contraindications.
I B
It is recommended to continue chronic beta-blocker therapy, unless the patient is in Killip class III or higher. I B
Acute coronary syndromes with persistent ST-segment elevation
Oral treatment with beta-blockers is indicated in patients with heart failure and/or LVEF £ 40% unless 
contraindicated.
I A
Routine oral treatment with beta-blockers should be considered during hospital stay and continued thereafter in 
all patients without contraindications.
IIa B
Arterial hypertension
Diuretics (thiazides, chlorthalidone and indapamide), beta-blockers, calcium antagonists, ACE inhibitors, 
and angiotensin receptor blockers are all suitable and recommended for the initiation and maintenance of 
antihypertensive treatment, either as monotherapy or in some combinations with each other.
I A
Heart failure
An ACEI is recommended, in addition to a beta-blocker, for symptomatic patients with HFrEF to reduce the risk 
of HF hospitalization and death.
I A
A beta-blocker is recommended, in addition to an ACEI , for patients with stable, symptomatic HFrEF to reduce 
the risk of HF hospitalization and death.
I A
ACEI – angiotensin converting enzyme inhibitors; HFrEF – heart failure with reduced ejection fraction 
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roborate the effectiveness of b-blocker therapy among 
patients after MI treated with coronary angioplasty [23]. 
Patients treated with b-blockers after discharge from the 
hospital were characterized by lower mortality during 
a 12-month follow-up period (unadjusted relative risk 
[RR] 0.58, 95% CI 0.48-0.71; adjusted HR 0.76, 95% CI 
0.62-0.94) compared to those who did not receive such 
a treatment. However, the benefits of b-blocker therapy 
were limited to patients with impaired left ventricular 
function or to patients with NSTEMI. 
In the era of reperfusion, contrast-induced nephropathy 
is a frequently observed complication, especially among 
elderly patients with renal impairment at baseline. In a study 
conducted on 200 patients undergoing coronarography, of 
which one half received carvedilol and the other half was 
treated with metoprolol, contrast-induced nephropathy 
occurred in 7 patients (7%) treated with carvedilol and 
22 (22%) patients on metoprolol (p=0.003) [24]. 
Lower incidence of contrast-induced nephropa-
thy in the group treated with carvedilol is probably 
attributed to antioxidative properties of the drug. 
The anti-arrhythmic effect also constitutes one of 
the major benefits of carvedilol. A meta-analysis of four 
randomized studies that included a total of 601 patients 
with CAD undergoing coronary artery by-pass grafting 
compared the effects of carvedilol and metoprolol on the 
occurrence of atrial fibrillation during the perioperative 
period [25]. There was significantly lower incidence 
of atrial fibrillation in the group of patients treated with 
carvedilol compared to the group taking metoprolol (OR 
0.50; 95% CI 0.32-0.80). The observed anti-arrhythmic 
effect is also attributed to the antioxidative properties 
of the drug, as well as its effect on ionic currents in 
cardiomyocytes [26]
According to the summary of product characteristics, 
the initial recommended dose of carvedilol is 12.5 mg 
BID for the first two days, followed by 25mg BID [27].
Carvedilol in patients with arterial 
hypertension
The 2013 guidelines on management of arterial 
hypertension elaborated by the European Society of 
Hypertension and the ESC consistently recommend 
b-blockers as one of five first-choice drug groups next 
to; ACEI, ARB, thiazide diuretics, and calcium antago-
nists (Table 1) [28]. The same position may be found 
in a document “Principles of management of arterial 
hypertension in 2015” by the Polish Society of Arterial 
Hypertension (PTNT) [29]. In some specific clinical 
situations b-blockers should be preferred over other 
groups of drugs, e.g. in patients with a history of MI, 
with angina pectoris, heart failure, aortic aneurysm, 
tachycardia, arrhythmia, or with hyperkinetic circulation. 
 Combination therapy plays an important role in the 
treatment of arterial hypertension. Optimal drug com-
binations with b-blockers include ACEI and dihydropy-
ridine calcium antagonists. Despite numerous studies 
demonstrating limitations of b-blocker use in patients 
with arterial hypertension, a meta-analysis published 
by Law et al. confirmed similar efficacy of b-blockers in 
prevention of coronary events and very good efficacy in 
prevention of cardiovascular events in patients after MI 
or with heart failure compared to other first-line drugs 
[30-32]. The most important limitations of b-blockers 
found in the literature include: smaller effect on central 
blood pressure and pulse pressure compared to other 
classes of drugs, smaller efficacy regarding regression 
of left ventricular hypertrophy, as well as unfavorable 
metabolic profile, especially in combination with di-
uretics, associated with elevated risk of diabetes or 
weight gain [33-35]. Carvedilol undoubtedly stands out 
against all available b-blockers due to its vasodilative 
properties, making it a preferred agent for the treatment 
of uncomplicated arterial hypertension according to 
the PTNT guidelines [29]. The principal mechanism, 
in which b-blockers reduce blood pressure, includes 
decrease in cardiac output, sympathetic activity and 
production of renin by the cells of juxtaglomerular 
apparatus accompanied by an increase in peripheral 
resistance, which is an undesirable effect. Carvedilol, 
due to the blockade of a1 receptors, lowers blood pres-
sure by reducing peripheral vascular resistance, while 
cardiac output remains generally unaffected. In this 
manner, its hemodynamic profile is similar to ACEI or 
calcium antagonists [36]. Another favorable mechanism 
of carvedilol’s vasodilative effect involves stimulation of 
nitric oxide production by endothelial cells [37]. 
Randomized GEMINI trial was designed in order to 
address the reports suggesting unfavorable metabolic 
profile of b-blockers [38]. This randomized, double-blind 
study included 1235 patients with type 2 diabetes and 
arterial hypertension. Participants were assigned to 
carvedilol (498 patients) or metoprolol (737 patients) 
BID in gradually increasing doses. Primary endpoint 
consisted of mean change in glycated hemoglobin 
(HbA1c) concentration measured at baseline and after 
5 months of therapy. Secondary endpoints consisted of 
improvement in insulin sensitivity and microalbuminuria. 
Significant increase in HbA1c concentration was noted 
in the group of patients treated with metoprolol (mean: 
0.15%, p<0.001) – an effect that was not seen in patients 
treated with carvedilol (mean: 0.02%; p=0.65). More-
over, improvement in insulin sensitivity was observed 
in the carvedilol group (-9.1%; p=0.004) compared to 
metoprolol (-2.0%; p=0.48). Concluding, over several 
months of follow-up therapy with carvedilol improved 
metabolic profile of patients with type 2 diabetes and 
arterial hypertension compared to metoprolol. 
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Left ventricular hypertrophy is one of the com-
plications of arterial hypertension and a significant 
cardiovascular risk factor. The majority of hypotensive 
agents possess the ability to reverse cardiac hyper-
trophy, although this effect was not demonstrated for 
selective b-blockers [39]. In a study by Galzerano et al. 
carvedilol reduced cardiac hypertrophy in patients with 
arterial hypertension, although it was less effective than 
telmisartan in that regard [40]. 
Hypertensive nephropathy is another complication 
of arterial hypertension. It leads to reduction in renal 
blood flow and, as a result, drop in glomerular filtration. 
Traditional b-blockers cause an additional decrease in 
renal blood flow. There are several studies corroborat-
ing the nephroprotective effects of carvedilol, in which 
the drug increased renal blood flow and reduced micro-
albuminuria [41]. In the aforementioned GEMINI trial, 
among patients with arterial hypertension and diabetes, 
but without microalbuminuria at baseline, carvedilol was 
less likely to induce it compared to metoprolol (6.4% 
vs. 10.3%; OR 0.60; 95% CI 0.36-0.97; p=0.04) [38]
According to the summary of product character-
istics, in treatment of arterial hypertension the initial 
recommended dose of carvedilol is 12.5 mg OD for the 
first two days, followed by 25mg OD. It is also allowed 
to increase the dose to 50 mg OD or divided into two 
doses [27]. Stienen et al. presented a rationale for such 
dosing of carvedilol in patients with arterial hypertension 
in his meta-analysis [42]. 
Clinical application of carvedilol in 
patients with heart failure
Beta receptor antagonists constitute the basis of 
treatment of heart failure, reducing mortality and mor-
bidity in this group of patients [43,44]. According to the 
ESC guidelines, b-blockers in combination with ACEI 
are recommended for stable, symptomatic patients 
with heart failure and reduced left ventricular ejection 
fraction in order to reduce the risk of hospitalization due 
to heart failure or death (Table 1) [6]. In our previous 
publication we discussed the most important studies 
that made carvedilol the leading agent for treatment 
of patients with heart failure regardless of the severity 
of symptoms assessed according to the NYHA scale 
[44-48] (Table 2). 
One of the most important randomized studies 
involving carvedilol was the COMET trial, which demon-
strated superiority of treatment with carvedilol compared 
to metoprolol, expressed as 17% reduction in all-cause 
mortality in the group of patients with NYHA II-IV heart 
failure, left ventricular ejection fraction <35%, who 
received optimal pharmacological treatment (HR 0.83; 
95% CI 0.74-0.93; p=0.0017) [48]. In 2007 a subanalysis 
of the COMET trial was published aiming to assess the 
mechanism, in which carvedilol reduced all-cause mor-
tality compared to metoprolol and whether it as owed to 
reduction in mortality of some specific cause [49]. Over 
a mean follow-up period of 58 months, 1112 of 3029 pa-
tients died, including 972 deaths of cardiovascular 
causes (480 sudden deaths, 365 deaths due to heart 
failure and 51 deaths due to stroke). Multivariable Cox 
regression analysis demonstrated significant reduction 
in cardiovascular deaths (RR 0.80; 95% CI 0.7-0.91; 
p=0.0009), sudden deaths (RR 0.77; 95% CI 0.64-0.93; 
p=0.0073), and strokes (RR 0,37; 95% CI 0,19-0,71; 
p=0,0027), as well as a trend toward reduction in the 
rate of death secondary to heart failure (RR 0.83; 95% 
CI 0.66-1.04; p=0.07) in patients treated with carvedilol 
compared to metoprolol. Summarizing, in the group of 
patients with heart failure carvedilol was more effective 
in reducing the risk of death regardless of its cause. 
Another interesting analysis compared the results of 
major randomized clinical trials that influenced current 
standards of care in heart failure: CIBIS-II (bisoprolol), 
COPERNICUS (carvedilol), SENIORS-SHF (nebivolol), 
and MERIT-HF (metoprolol) [Wikstrand] [50]. Since 
these studies differed with regard to inclusion criteria, it 
was necessary to select groups of patients among stud-
ied populations in order to allow reliable comparison. 
Reference group that other results were compared to 
consisted of patients from MERIT-HF trial. Similar effica-
cy and satisfactory tolerance of treatment was noted for 
carvedilol, bisoprolol and metoprolol in the population 
of patients with heart failure regardless of NYHA class 
or degree of left ventricular dysfunction, while the effi-
cacy of treatment with nebivolol was lower with similar 
tolerance. Moreover, lower rate of discontinuation of 
the study medication was noted in the carvedilol group. 
The CARMEN trial was the first study to prove that 
early administration of ACEI combined with carvedilol 
leads to reversal of pathological left ventricular remodel-
ing in the group of patients with mild to moderate heart 
failure [51]. The analysis included 572 patients, who 
were randomly assigned to one of three arms: in one 
arm patients received carvedilol (190), in the second - 
enalapril (190), and in the third arm patients received 
a combination of the two (191). Over the course of the 
study, which lasted 18 months, medication doses were 
gradually increased to maximally tolerated. Primary 
endpoint consisted of left ventricular remodeling defined 
as change in end-diastolic volume assessed in trans-
thoracic echocardiography. Treatment with both drugs 
resulted in significant reduction in the left ventricular 
end-diastolic volume index compared to treatment with 
enalapril alone (p=0.0015), proving that it is possible to 
reverse unfavorable left ventricular remodeling. 
Another study that corroborated the beneficial 
effects of carvedilol on left ventricular systolic func-
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tion was the CHRISTMAS trial [52]. Analysis included 
305 patients with chronic heart failure of atherosclerotic 
etiology. Patients were randomized to carvedilol or 
placebo and followed-up lasted for 6 months. Signif-
icant increase in left ventricular ejection fraction was 
observed in patients treated with carvedilol compared 
to placebo (p<0.0001). Also, greater improvement in 
left ventricular systolic function was shown in the group 
of patients with larger area of stunned or stunned and 
ischemic myocardium.
There is an ongoing debate regarding selection of 
an optimal b-blocker for patients with heart failure and 
results of new studies are constantly emerging. Based 
on the data from a national Danish registry Pasternak et 
al. led a cohort study on patients with heart failure and 
impaired systolic function of the left ventricle (≤40%), 
which included 6026 patients treated with carvedilol 
and 5638 patients receiving metoprolol succinate [53]. 
Follow-up lasted for a median of 2.4 years, during 
which there were 875 deaths in the carvedilol group 
and 754 in the metoprolol group (18.3% vs. 18.8%; 
corrected HR 0.99; 95% CI 0.88-1.11). The risk of death 
due to cardiovascular causes did not differ significantly 
between the two groups (corrected HR 1.05; 95% CI 
0.88-1.26). Results of this study suggest similar efficacy 
of treatment with carvedilol compared to metoprolol with 
regard to both all-cause and cardiovascular mortality. 
Another study aiming to explain whether the re-
duction in mortality associated with b-blockers can be 
attributed to a class effect or does it differ for specific 
compounds encompassed 6010 stable patients with 
heart failure and reduced ejection fraction from 3 na-
tional registries: Norwegian, British, and German [54]. 
The study analyzed mortality among patients receiving 
bisoprolol – 302 (29.5%), carvedilol – 637 (37.0%), or 
metoprolol succinate – 1232 patients (37.7%). Univariate 
analysis showed that all-cause mortality was lower in the 
group treated with bisoprolol compared to metoprolol 
(HR 0.80, 95% CI 0.71-0.91, p < 0.01) and in the carve-
dilol arm compared to metoprolol group (HR 0.86, 95% 
CI 0.78-0.94, p < 0.01), while bisoprolol seemed to be 
equally effective as carvedilol (HR 0.94, 95% CI 0.82-
1.08, p = 0.37). However, in propensity score analysis, 
where patients were matched with regard to the type 
of b –blocker used and its dose, it appeared that the 
type of b-blocker did not significantly impact mortality 
(bisoprolol vs. carvedilol: HR 0.90; 95% CI 0.76-1.06; 
p = 0.20; bisoprolol vs. metoprolol HR 1.10, 95% CI 
0.93-1.31, p = 0.24; and carvedilol vs. metoprolol HR 
1.08, 95% CI 0.95-1.22, p = 0.26).
The above observations are not in line with an article 
recently published in American Heart Journal, which re-
ported superiority of carvedilol compared to metoprolol 
succinate in the largest to date group of patients with 
heart failure and impaired left ventricular systolic func-
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tion [55]. Primary analysis included 114 745 patients 
with heart failure treated with carvedilol or metoprolol 
and, after propensity score analysis, patients were 
matched with regard to age, sex, comorbidities, other 
medication and their doses, resulting in homogeneous 
groups of 43 941 patients in each arm of the study. 
Higher mortality was noted among patients treated with 
metoprolol compared to carvedilol (corrected HR 1.069; 
95% CI 1.046-1.092; p<0.001) over a 3.5-year observa-
tion period, while in a 6-year prognosis the probability of 
survival was higher in patients on carvedilol compared 
to the metoprolol group (55.6% vs. 49.2%; p<0.001).
Nebivolol is another, beside carvedilol, third-gener-
ation b-blocker with vasodilative properties. The aim of 
a study conducted by Patrianakos et al. was to compare 
the effects of carvedilol vs nebivolol on function of the 
left ventricle and exercise capacity in 72 patients with 
heart failure due to dilated cardiomyopathy [56]. Carve-
dilol arm consisted of 38 patients, while 34 subjects 
received nebivolol. Echocardiographic examination and 
exercise tests were conducted before the commence-
ment of treatment, after 3 and 12 months of therapy. 
Improvement in left ventricular function in relation to 
baseline values was observed during treatment with 
both compounds, although greater improvement was 
noted in the group treated with carvedilol compared 
to nebivolol, both after three months (p=0.004) and 
after a year (p=0.02). Moreover, among patients in 
the carvedilol arm, improvement in diastolic function 
was observed after only 3 months of therapy (p=0.02), 
while in the nebivolol group gradual improvement was 
observed after as long as a year (p=0.02). Exercise 
capacity was enhanced over a 1-year follow-up period 
in both study groups (p=0.01 for both groups), although 
in the nebivolol group researchers observed transient 
worsening after 3 months of treatment (p=0.07).
Conclusions 
Possible indications for carvedilol are very broad 
and, due to its unique properties that go far beyond the 
traditional b receptor blockade, the drug may be used 
as a hypotensive, anti-anginal, or anti-arrhythmic agent, 
however, it is definitely the number one choice for the 
treatment of patients with heart failure. Despite being 
a non-selective b-blocker, due to concomitant a1 recep-
tor blockade it exhibits vasodilative action and avoids 
the disadvantages associated with this generation of 
b-blockers. Patients, who gain the greatest benefit from 
carvedilol therapy are those with heart failure, after MI, 
with impaired left ventricular function, at risk of devel-
oping life-threatening arrhythmias or atrial fibrillation. 
Among numerous patients with arterial hypertension, 
carvedilol will be a particularly good choice for young 
patients, with hyperkinetic circulation, or arrhythmias, 
women of child-bearing age, or patients with coexisting 
metabolic syndrome. hyperlipidemia or diabetes and 
indications for b-blockade. It should be also empha-
sized that in randomized, double-blind clinical trials 
carvedilol reduced hard endpoints, such as mortality, 
compared to placebo. The evidence from numerous 
studies comparing carvedilol to other drugs of the 
same class also corroborates the uniqueness of this 
compound. Typical blockade of b receptors, favorable 
metabolic profile, and beneficial hemodynamic profile 
due to a1 receptor antagonism combined with vastness 
of pleiotropic effects make carvedilol a leader among 
b-blockers across all of its indications. 
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